STAAR Surgical (NASDAQ:STAA) Shares Bought by Assenagon Asset Management S.A.

Assenagon Asset Management S.A. lifted its holdings in shares of STAAR Surgical (NASDAQ:STAA) by 2.3% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 90,434 shares of the medical instruments supplier’s stock after acquiring an additional 2,047 shares during the quarter. Assenagon Asset Management S.A. owned 0.18% of STAAR Surgical worth $3,360,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of STAA. Covestor Ltd raised its position in shares of STAAR Surgical by 38.9% in the 1st quarter. Covestor Ltd now owns 2,690 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 754 shares in the last quarter. Canada Pension Plan Investment Board acquired a new stake in STAAR Surgical in the second quarter valued at $129,000. Larson Financial Group LLC bought a new position in STAAR Surgical during the 2nd quarter valued at $130,000. nVerses Capital LLC grew its holdings in STAAR Surgical by 78.3% during the 3rd quarter. nVerses Capital LLC now owns 4,100 shares of the medical instruments supplier’s stock worth $152,000 after acquiring an additional 1,800 shares in the last quarter. Finally, Creative Planning increased its position in shares of STAAR Surgical by 8.0% in the 3rd quarter. Creative Planning now owns 5,524 shares of the medical instruments supplier’s stock worth $205,000 after purchasing an additional 408 shares during the last quarter. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Transactions at STAAR Surgical

In other STAAR Surgical news, Director Arthur C. Butcher bought 1,315 shares of the business’s stock in a transaction on Monday, August 12th. The shares were purchased at an average price of $37.99 per share, with a total value of $49,956.85. Following the purchase, the director now directly owns 4,208 shares of the company’s stock, valued at approximately $159,861.92. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 1.00% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently commented on STAA shares. Needham & Company LLC reiterated a “hold” rating on shares of STAAR Surgical in a research note on Thursday, September 19th. Morgan Stanley downgraded STAAR Surgical from an “equal weight” rating to an “underweight” rating and lowered their price target for the company from $50.00 to $37.00 in a report on Monday, July 15th. Canaccord Genuity Group reduced their price objective on STAAR Surgical from $43.00 to $41.00 and set a “hold” rating on the stock in a research note on Thursday, August 8th. Stifel Nicolaus lowered their target price on shares of STAAR Surgical from $50.00 to $44.00 and set a “buy” rating for the company in a research note on Monday, August 26th. Finally, BTIG Research increased their target price on shares of STAAR Surgical from $46.00 to $53.00 and gave the stock a “buy” rating in a report on Monday, July 15th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $45.57.

STAAR Surgical Stock Performance

STAA stock opened at $29.49 on Thursday. STAAR Surgical has a 1 year low of $26.66 and a 1 year high of $52.68. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of 86.74 and a beta of 0.59. The stock’s fifty day moving average is $32.06 and its two-hundred day moving average is $38.76.

STAAR Surgical (NASDAQ:STAA) last posted its earnings results on Wednesday, August 7th. The medical instruments supplier reported $0.15 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.24 by ($0.09). STAAR Surgical had a net margin of 4.99% and a return on equity of 5.60%. The firm had revenue of $99.01 million for the quarter, compared to analyst estimates of $95.22 million. During the same period in the previous year, the firm earned $0.23 earnings per share. The company’s revenue for the quarter was up 7.3% on a year-over-year basis. As a group, analysts predict that STAAR Surgical will post 0.16 EPS for the current fiscal year.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.